Santhera nabs Stephanie Brown as president North America

Swiss rare diseases specialist Santhera Pharmaceuticals (SIX: SANN) today said it has appointed Stephanie Brown as president North America and a member of its executive management team, effective December 1.

Ms Brown joins Santhera with an extensive background leading commercial businesses and global franchises in North America and Europe. Most recently, she was senior vice president and head of the Rare Diseases Franchise, North America at French drugmaker Ipsen (Euronext: IPN). In this role, she was responsible for establishing a new rare disease business unit to market and launch medicines to treat rare conditions.

Prior to Ipsen, Ms Brown was VP and US head of Novartis’ (NOVN: VX) Neuroscience Franchise with responsibility for commercial marketing, sales and operations of this important business and had oversight of market access, patient services and medical affairs. Earlier in her career, Ms Brown held various leadership roles at Takeda Pharmaceuticals US, Biogen, Genentech and Merck.